Non-invasive Optical Angiography in Age-related Macular Degeneration

Status Recruiting

Clinical Trial Summary

Age-related macular degeneration (AMD) is the leading cause of severe and irreversible visual loss and classified blindness in the elderly throughout Europe and the US. Among these patients, about 6%-8% are afflicted with the advanced stages of AMD, which are responsible for the most severe visual loss. There is now convincing evidence that vascular endothelial growth factor (VEGF) is a major trigger for the formation of pathological choroidal vessels, responsible for the development of the neovascular form of AMD. Today, the gold standard for vascular imaging of the retina and diagnosis of CNV is angiography using fluorescein (FLA) or indocyanine green (ICG), which involves injection of the dye into a vein of the arm. In the recent years tremendous enhancements in the field of optical coherence tomography have been achieved. These developments made it possible to visualize the retinal vasculature in a full depth manner without the application of an intravenous marker. The proposed study tests the hypothesis that visualisation of CNV lesion size with non-invasive OCT angiography is not inferior to FLA/ICG angiography in treatment naïve and previously treated AMD patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02521142
Study type	Observational
Source	Medical University of Vienna
Contact	Andreas Pollreisz, MD
Phone	+4314040048470
Email	andreas.pollreisz@meduniwien.ac.at
Status	Recruiting
Phase
Start date	November 2015
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03963817` - Snapshot Camera for AMD
Recruiting	`NCT04929756` - Eye Movement Rehabilitation in Low Vision Patients
Completed	`NCT04779398` - Association of MPOD Values With Blue Light.
Terminated	`NCT03275753` - Visual Function Tests in Age-related Macular Degeneration
Recruiting	`NCT03609307` - Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial	Phase 2/Phase 3
Completed	`NCT02909985` - Visual Activity Evoked by Infrared in Humans After Dark Adaptation	N/A
Completed	`NCT02556723` - Intravitreal Injections of Ziv-aflibercept for Macular Diseases	N/A
Active, not recruiting	`NCT01943396` - Treatment of AMD With Rheohemapheresis /RHF/	Phase 4
Completed	`NCT00963339` - Age-Related Macular Degeneration (AMD) - Usability Study	N/A
Completed	`NCT00376701` - Combination Therapy for Age-Related Macular Degeneration.	Phase 2
Completed	`NCT00800995` - Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)	Phase 3
Terminated	`NCT00347165` - Intravitreal Bevacizumab for Age-Related Macular Degeneration	Phase 2
Completed	`NCT04689789` - OCTA and Retinal Angiomatous Proliferation
Completed	`NCT02567604` - Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
Completed	`NCT02173496` - Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
Recruiting	`NCT01991730` - Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients	N/A
Active, not recruiting	`NCT01657669` - Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results	Phase 4
Completed	`NCT00791570` - Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy	Phase 1
Completed	`NCT00776763` - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab	Phase 2
Completed	`NCT00413829` - Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)	Phase 2